SecBot SecBot
PRESS-RELEASE ·Filed Aug 14, 2026

SKYE

Skye Bioscience, Inc.
BEARISH
Impact 7/10
Horizonmonths Processed3mo ago WireGlobeNewswire
Press release · Activist
Actionable Insight ▼ Bearish

For SKYE holders, the transaction represents extreme dilution with only 5.38% pro-forma ownership. Monitor shareholder vote and potential for competing bids. The CVR provides some contingent upside but is highly uncertain. The combined company's cash runway into 2029 and RXC008 Phase 2 catalyst in H2 2028 are the key value drivers for the new entity.

DirectionBearish
Confidencehigh
Horizonmonths

Drugs in focus

SKYE drug pipeline →

nimacimab

▼ Bearish Named in this press release
Impact
Phase
Phase 2a
Time to market
Likely years away if ever; nimacimab is currently in Phase 2a (Part C expansion), with Phase 2b design under FDA review but not yet funded. The Redx reverse merger monetizes the asset via CVR — further development by Skye/Fibrx is uncertain.
Next catalyst
None dated

What to watchMonitor the Q4 2026 Part C expansion topline data for nimacimab, which could drive value in the CVR. However, with the Redx reverse merger pending (expected Q4 2026 close), pre-merger SKYE shares now primarily represent ~5.38% of the future Fibrx Therapeutics, with nimacimab upside limited to the CVR, extreme caution is warranted for equity holders.

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$0.5015
T+0 close · Aug 14, 2026 · via day close
Latest settled
−82.80%
T+60 · $0.0862
Vs SPY
−79.76%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 14 $0.5015entry
  2. T+1 · 3mo ago −17.23%α −16.76% · $0.4151
  3. T+5 · 3mo ago −44.17%α −42.80% · $0.2800
  4. T+20 · 2mo ago −50.40%α −48.41% · $0.2487
  5. T+60 · 8d ago −82.80%α −79.76% · $0.0862

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Skye Bioscience announces a reverse merger with private UK biotech Redx Pharma, forming Fibrx Therapeutics focused on fibrosis. Pre-Transaction Skye shareholders will own only ~5.38% of the combined company, representing extreme dilution. The combined entity receives $125M in committed financing to fund RXC008 through Phase 2 topline data expected H2 2028.

Key Facts

  • Skye to acquire Redx Pharma via scheme of arrangement; combined company to be named Fibrx Therapeutics
  • Pre-Transaction Skye equity holders to own approximately 5.38% of the combined company
  • Pre-Transaction Redx holders to own ~46.17%; Financing investors to own ~48.45%
  • Aggregate financings of approximately $125 million committed (PIPE $68M, Series A $36M, Equity Line Facility up to $22M)
  • Lead asset RXC008 (GI-restricted pan-ROCK inhibitor) for fibrostenotic Crohn's disease, Phase 2 ready with topline data expected H2 2028
  • Skye shareholders to receive CVRs entitling them to 90% of net proceeds from monetization of nimacimab within 12 months post-close
  • Expected transaction close in Q4 2026, subject to shareholder and regulatory approvals
  • Redx management team to lead combined company; headquarters in Alderley Park, UK

Financial Impact

Skye shareholders diluted to ~5.38% ownership; combined company receives ~$125M in new financing; CVR provides contingent upside from nimacimab monetization

dilutionownershipcash runway

Risk Factors

  • Transaction may fail to close due to shareholder or regulatory approval
  • Extreme dilution for existing Skye shareholders
  • CVR may yield minimal or no proceeds if nimacimab is not monetized
  • RXC008 Phase 2 clinical risk; fibrostenotic Crohn's is a high-unmet-need but unproven target
  • Integration risk and execution risk under new management

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
77% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3345392

Track record

16 reports on SKYE

Performance horizon

4 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +42.05% at T+60 after the May 12, 2026 report. 5 of 5 went positive at some point.

Filters
  1. Nov 12, 20264d ago DEFA14A Neutral 3/10 Entry $1.08 Now $1.07 −1.39% settles Dec 11
  2. Nov 12, 20264d ago 8-K Neutral 3/10 Entry $1.08 Now $1.07 −1.39% settles Dec 11
  3. Oct 26, 202621d ago PREM14A Bearish 7/10 Entry $1.45 Now $1.07 +26.55% settles Nov 24
  4. Oct 14, 20264w ago SC 13G Neutral 4/10 Entry $1.59 to $1.08 Now $1.07 −33.02% ▼ −32.08% −30.17% vs SPY
  5. Sep 24, 20267w ago Insider Cluster Neutral 3/10 Entry $1.67 to $1.54 Now $1.07 −36.23% ▼ −7.78% −6.31% vs SPY
  6. Sep 24, 20267w ago SC 13D/A Bearish 6/10 Entry $1.67 to $1.54 Now $1.07 +36.23% ▲ +7.78% +6.31% vs SPY
  7. Sep 18, 20268w ago Insider Cluster Bearish 4/10 Entry $1.78 to $1.53 Now $1.07 +40.17% ▲ +14.04% +13.14% vs SPY
  8. Aug 19, 202612w ago DEFA14A Neutral 4/10 Entry $0.2809 to $0.2206 Now $1.07 +279.14% ▼ −21.46% −21.34% vs SPY
  9. Aug 14, 202613w ago 8-K Mixed 7/10 Entry $0.5015 to $0.2487 Now $1.07 +112.36% ▼ −50.40% −48.41% vs SPY
  10. Aug 14, 202613w ago Press Release Bearish 7/10 Viewing Entry $0.5015 to $0.2487 Now $1.07 −112.36% ▲ +50.40% +48.41% vs SPY
Showing 10 of 16

US Market Status

Market Closed · Opens in 6h 40m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 14, 2026